RISE now has three means of reporting through the Merit-Based Incentive Payment System (MIPS): individual, group and the recently added virtual groups. According to the CMS, virtual groups allow individual MIPS-eligible clinicians or groups consisting of not more than 10 MIPS-eligible clinicians to join together and report as if they were a single entity. The…
The Rheumatology Clinical Registry Is Now Open for Reporting
The Rheumatology Clinical Registry (RCR) is open for reporting. As we are approaching the end of the 2017 MIPS performance year, however, keep in mind that to report via the RCR, your last date to enter patient information will be Jan. 15, 2018. You can access the RCR’s updated dashboard here. Remember to use your…
The ACR Lobbies Against New Part B Drug Cost Adjustment Rule
The ACR and a number of other physician medical associations are lobbying for an immediate legislative fix to a piece of the MACRA law that factors high-cost Part B drugs into a rheumatology practice’s Medicare reimbursement rate through the Merit-Based Incentive Payment System (MIPS). This change, which goes into effect immediately, will impact practices in…
RISE: What’s New for You in 2018?
Medicare’s Merit-Based Incentive Payment System (MIPS) has been on a gradual incline toward requiring full participation by eligible providers. During its transition stage, reporting for the first year (2017) allowed providers the option to report as partial, full, minimum or not at all, with varying degrees of penalties and incentives across all three reporting components:…
Upadacitinib Promising for RA in Phase 3 Study
In a recent study, upadacitinib proved safe and effective to treat rheumatoid arthritis in patients with inadequate responses to conventional synthetic DMARDs…
Safety, Tolerability & Pharmacodynamics of ABT-122 in Patients with RA
The introduction of biologic disease-modifying anti-rheumatic drugs (DMARDs) has greatly expanded the treatment options for managing rheumatoid arthritis (RA). In many patients, biologic DMARDs improve clinical symptoms, improve function and slow disease progression. Biologic DMARDs are recommended as add-on treatment to conventional synthetic DMARDs, such as methotrexate (MTX) in patients who experienced an incomplete response…
Patients Have Different Hospital Outcomes When Regular Doctors See Them
(Reuters Health)—Many outcomes for hospital patients—including how long they stay and their survival odds after they go home—may depend on whether or not they’re cared for by their primary care physician, a U.S. study suggests. Researchers examined data on 560,651 admissions nationwide for patients covered by Medicare, the U.S. health program for the elderly and…
CVS Health to Acquire Aetna for $69 billion
(Reuters)—U.S. drugstore chain operator CVS Health Corp said on Sunday it had agreed to acquire U.S. health insurer Aetna Inc. for $69 billion, seeking to tackle soaring healthcare spending through lower-cost medical services in pharmacies. This year’s largest corporate acquisition will combine one of the nation’s largest pharmacy benefits managers (PBMs) and pharmacy operators with…
Healthcare Prices Hard to Find Online
(Reuters Health)—Consumers who search online for prices of common medical procedures may be disappointed by what they find, a U.S. study suggests. Researchers used the search engines Google and Bing to check the cost of common services like cholesterol tests, hip replacements and magnetic resonance imaging (MRI) scans in 8 cities: New York; Los Angeles;…
Lacrimal & Tear Fluid Yield Clues to Dry Eye Disease
A recent study suggests novel markers of dry eye disease can be found in the lacrimal fluid and tear fluid of patients. Researchers analyzed the proteins in these fluids and found immune response-related proteins are upregulated at the protein level in lacrimal fluid of patients with dry eye disease and may be an important biomarker…
- « Previous Page
- 1
- …
- 360
- 361
- 362
- 363
- 364
- …
- 798
- Next Page »